Abstract
SummaryThis review is comprized of two sections. The first discusses the life-cycle of HIV and potential target sites for anti-HIV drugs. The second reviews anti-HIV agents, which are limited to proteins and peptides in this article. Agents that interfere with events early in the HIV life-cycle are divided into two categories, those that interfere with events prior to viral entry and those that are active after viral entry but prior to proviral integration. These agents can abort virus infection if appropriately used. In contrast, agents interfering with events late in the HIV life-cycle do not abort HIV infection, rather, they suppress events during viral replication such as gene transcription, translation and/or virus assembly and maturation. It is likely that combination therapy with agents inhibiting an event early and another event late in the HIV life-cycle will be most efficacious.Soluble CD4, chimaeric molecules of CD4 and IgG, neutralizing antibodies and N-carbomethoxy-carbonyl-prolyl-phenylalany...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
